HUP0100582A2 - Eljárás oxiranil-epotilonok redukálására olefines epotilonokká - Google Patents

Eljárás oxiranil-epotilonok redukálására olefines epotilonokká

Info

Publication number
HUP0100582A2
HUP0100582A2 HU0100582A HUP0100582A HUP0100582A2 HU P0100582 A2 HUP0100582 A2 HU P0100582A2 HU 0100582 A HU0100582 A HU 0100582A HU P0100582 A HUP0100582 A HU P0100582A HU P0100582 A2 HUP0100582 A2 HU P0100582A2
Authority
HU
Hungary
Prior art keywords
alkyl
substituted
epothilones
group
general formula
Prior art date
Application number
HU0100582A
Other languages
English (en)
Inventor
James A. Johnson
Soong-Hoon Kim
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0100582A2 publication Critical patent/HUP0100582A2/hu
Publication of HUP0100582A3 publication Critical patent/HUP0100582A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya eljárás (II) és (IV) általános képletű vegyületekelőállítására (I.), illetve (III) általános képletű vegyületekből -ahol W -O- vagy -NR8- általános képletű csoport; R1, R2, R3, R4, R5,R6 hidrogénatom, alkil-, szubsztituált alkil- vagy aril-csoport, vagyR1 és R2 cikloalkil-csoportot képezhetnek; R7 hidrogénatom, alkil-,szubszitutált alkil-, aril-, cikloalkil- vagy heterociklusos csoport;R8 hidrogénatom, alkil- vagy szubsztituált alkil-, hidroxi-, alkoxi-,szubsztituált alkoxi-csoport; P1 és P2 hidrogénatom, alkil-,szubsztituált alkil-, alkanoil-, szubsztituált alkanoil-, aroil-,szubsztituált aroil-, trialkil-szilil-, aril-dialkil-szilil-, diaril-alkil-szilil-, triaril-szilil-csoport - a[N2C (CO2Me)2, kat Rh2,(OAC)4];[N2C (CO2Me)2, kat (n-C7H15CO2)2Rh]2;[Zn-Cu, EtOH]; (Mg(Hg),MgBr]; Cr,[FeC13, n-BuLi];[TiCl3, LiA1H4];[TiCl4, Zn];[WC16,LiA1H4];[NbCl5, NaA1H4];[VC13, Zn] és[WC16, n-BuLi] reaktívmetallocének közül választott reagenssel végzett redukcióval. Ó
HU0100582A 1997-12-04 1998-12-01 A process for the reduction of oxiranyl epothilones to olefinic epothilones HUP0100582A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6754997P 1997-12-04 1997-12-04
US8256398P 1998-04-21 1998-04-21
PCT/US1998/025464 WO1999028324A1 (en) 1997-12-04 1998-12-01 A process for the reduction of oxiranyl epothilones to olefinic epothilones

Publications (2)

Publication Number Publication Date
HUP0100582A2 true HUP0100582A2 (hu) 2001-09-28
HUP0100582A3 HUP0100582A3 (en) 2003-03-28

Family

ID=26748002

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100582A HUP0100582A3 (en) 1997-12-04 1998-12-01 A process for the reduction of oxiranyl epothilones to olefinic epothilones

Country Status (13)

Country Link
EP (1) EP1042327B1 (hu)
JP (1) JP4434484B2 (hu)
KR (1) KR100574454B1 (hu)
AT (1) ATE250066T1 (hu)
AU (1) AU738576B2 (hu)
CA (1) CA2311929A1 (hu)
DE (1) DE69818304T2 (hu)
ES (1) ES2207015T3 (hu)
HK (1) HK1028401A1 (hu)
HU (1) HUP0100582A3 (hu)
IL (1) IL135590A (hu)
TW (1) TWI221469B (hu)
WO (1) WO1999028324A1 (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6320045B1 (en) * 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
JP2002504540A (ja) * 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
KR20050043796A (ko) * 2002-05-20 2005-05-11 코산 바이오사이언시즈, 인코포레이티드 에포틸론 d의 투여방법
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
MX368966B (es) 2011-06-10 2019-10-23 Mersana Therapeutics Inc Conjugados de proteina-polimero-farmaco.
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
TN2015000543A1 (en) 2013-06-11 2017-04-06 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
JP6427564B2 (ja) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー タンパク質−ポリマー−薬物共役体
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103936748A (zh) * 2014-05-08 2014-07-23 成都摩尔生物医药有限公司 一种埃博霉素b内酰胺衍生物的制备方法
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3641826B1 (en) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
US20210308207A1 (en) 2018-05-04 2021-10-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
EA202191175A1 (ru) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
US20230121556A1 (en) 2019-06-17 2023-04-20 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
CA3230774A1 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
EP4186529A1 (en) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104941A1 (en) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
WO2023158305A1 (en) 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE59609305D1 (de) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung

Also Published As

Publication number Publication date
DE69818304T2 (de) 2004-07-01
DE69818304D1 (de) 2003-10-23
JP2001525324A (ja) 2001-12-11
KR20010031976A (ko) 2001-04-16
AU738576B2 (en) 2001-09-20
HUP0100582A3 (en) 2003-03-28
ES2207015T3 (es) 2004-05-16
HK1028401A1 (en) 2001-02-16
EP1042327A4 (en) 2002-07-17
KR100574454B1 (ko) 2006-04-27
WO1999028324A1 (en) 1999-06-10
EP1042327A1 (en) 2000-10-11
IL135590A (en) 2003-09-17
IL135590A0 (en) 2001-05-20
AU1540899A (en) 1999-06-16
CA2311929A1 (en) 1999-06-10
JP4434484B2 (ja) 2010-03-17
TWI221469B (en) 2004-10-01
ATE250066T1 (de) 2003-10-15
EP1042327B1 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
HUP0100582A2 (hu) Eljárás oxiranil-epotilonok redukálására olefines epotilonokká
Padwa et al. Ylide formation from the reaction of carbenes and carbenoids with heteroatom lone pairs
TW217406B (hu)
WO2002004466A3 (en) Catalyst for asymmetric (transfer) hydrogenation
DE69835877D1 (de) Trizyklische verbindungen
ATE201195T1 (de) Tricyclische verbindungen
ATE106077T1 (de) Zyklopenta(d>pyrimidinderivate, ihre herstellung und verwendung.
EP0686636A4 (en) TRICYCLIC DERIVATIVES OF BENZAZEPINE AND BENZOTHIAZEPINE
ATE258551T1 (de) (2-(2-thienyl)-ethylamino)-(2-halophenyl)- acetonitrile als zwischenprodukte und verfahren zu ihrer herstellung
Binot et al. A convergent construction of quaternary centres and polycyclic structures
GB9604669D0 (en) Chemical compounds
ATE214061T1 (de) Azetidinonverbindung und verfahren zu ihrer herstellung
DE59806655D1 (de) Pyranone, verfahren zu ihrer herstellung und verwendung
EP0881220A4 (en) DIARYLSULTAME DERIVATIVES
MY118605A (en) Process for the preparation of a thiazolidinedione derivative
AU2001292350A1 (en) Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
AU5225398A (en) Compounds useful for perhalogenoalkylation, reagent for implementing these compounds and synthesis method for obtaining these compounds
MX9603616A (es) Derivados de ciclopentadienilo y procesos para su preparacion.
GB1525892A (en) Process for preparing 1-polyhaloalkyl-3,4-dihydro-2-(1h)-quinazolinones
DE69616357T2 (de) Benzocycloalken-verbindungen mit bindungsaffinität an den melatonin-rezeptor, ihre herstellung und verwendung
BR9809768A (pt) Aplicação de sulfoniloxadiazolonas como microbicidas
Nishio et al. Reduction of β-arylthio-or β-alkylthio-αβ-unsaturated ketones
AU2001288984A1 (en) 4-cyclohexyl-1,3,2-oxazaborolidine chiral accessories
Marecki et al. A new synthesis of naphtho [2, 3‐C] pyrroles. Conversion of naphtho [2, 3‐C] thiophene‐4, 9‐diones to naphtho [2, 3‐C] pyrrole‐4, 9‐diones
DE69900528T2 (de) Herstellung von Di-tert-peroxiden

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees